Key facts
- This page summarizes Adelene Q. Perkins's Form 4 filing for INFINITY PHARMACEUTICALS, INC..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Sep 2023, 18:20.
Adelene Q. Perkins - 08 Sep 2023 Form 4 Insider Report for INFINITY PHARMACEUTICALS, INC.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 08 Sep 2023
- Net transaction value
- -$28,714
- SEC form
- 4
- Accepted by SEC
- 12 Sep 2023, 18:20:24 UTC
- Prior SEC filing
- 09 Jan 2023
- Next SEC filing
- 09 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Adelene Q. Perkins
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Adelene Q. Perkins filed Form 4 for INFINITY PHARMACEUTICALS, INC. on 12 Sep 2023.
Change
- Previous filing in this sequence was filed on 09 Jan 2023.
- Current net transaction value: -$28,714.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INFI
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +768,133
- Change %
- +94%
- Price
- Shares after
- 1,585,487
- Date
- 09 Sep 2023
- Ownership
- Direct
- Footnotes
- F1
INFI
transaction
Common Stock
Sale
- Transaction value
- $28,714
- Shares
- -410,196
- Change %
- -26%
- Price
- $0.0700
- Shares after
- 1,175,291
- Date
- 12 Sep 2023
- Ownership
- Direct
- Footnotes
- F2
INFI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,447
- Date
- 08 Sep 2023
- Ownership
- 401(K)
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INFI
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -768,133
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 09 Sep 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 768,133
- Exercise price
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
Restricted stock units ("RSUs") convert into Common Stock of the issuer on a one-for-one basis. This transaction represents the settlement of RSUs in shares of Common Stock on their vesting date.
Footnote F2
Pursuant to a binding contract entered into between the issuer and the reporting person on August 15, 2022, this represents the shares automatically sold by the reporting person to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. Such binding contract is intended to be consistent with the affirmative action defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. This sale does not represent a discretionary trade by the reporting person.
Footnote F3
On August 11, 2022, the reporting person was granted RSUs, of which all 768,133 vested as of September 9, 2023.